Methods for the discovery of low-abundance biomarkers for urinary bladder cancer in biological fluids

Bioanalysis

Volumn 2, Issue 2, 2010, Pages 295-309

  Roos, Peter H ^a   Jakubowski, Norbert ^b  

^a TU DORTMUND UNIVERSITY   (Germany)

^b BAM FEDERAL INSTITUTE FOR MATERIALS RESEARCH AND TESTING   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 20; DNA FRAGMENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA; NUCLEIC ACID; PROTEIN; PROTEOME; RNA; TUMOR MARKER; UNCLASSIFIED DRUG; UROPLAKIN; UROPLAKIN II;

ANTIBODY ARRAY; APOPTOSIS; BLADDER CANCER; BLOOD; BODY FLUID; CANCER CELL; CHROMATOGRAPHY; DISEASE MARKER; DNA METHYLATION; GENE MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTIDIMENSIONAL CHROMATOGRAPHY; POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; TWO DIMENSIONAL GEL ELECTROPHORESIS; URINE; ANIMAL; BLADDER TUMOR; BLOOD ANALYSIS; GENETICS; ISOLATION AND PURIFICATION; METHODOLOGY; NUCLEOTIDE SEQUENCE; URINALYSIS;

ANIMALS; BASE SEQUENCE; BLOOD CHEMICAL ANALYSIS; HUMANS; NUCLEIC ACIDS; PROTEINS; TUMOR MARKERS, BIOLOGICAL; URINALYSIS; URINARY BLADDER NEOPLASMS;

EID: 79952502698     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.09.174     Document Type: Review

References (109)

1. Murta-Nascimento C, Schmitz-Dräger BJ, Zeegers MP, et al. Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J. Urol. 25, 285-295 (2007).
2. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas TB. Cancer Incidence in Five Continents, Volume VIII (No. 155). IARC Publications, Lyon, France (2002).
3. Margulis V, Lotan Y, Shariat SF. Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J. Urol. 26, 59-65 (2008).
4. Vrooman OP, Witjes JA. Urinary markers in bladder cancer. Eur. Urol. 53, 909-916 (2008).
5. Lam T, Nabi G. Potential of urinary biomarkers in early bladder cancer diagnosis. Expert Rev. Anticancer Ther. 7(8), 1105-1115 (2007). (Pubitemid 47370805)
6. Shariat SF, Zlotta AR, Ashfaq R, Sagalowsky AI, Lotan Y. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod. Pathol. 20, 445-459 (2007). (Pubitemid 46482368)
7. Mitra AP, Birkhahn M, Cote RJ. p53 and retinoblastoma pathways in bladder cancer. World J. Urol. 25, 563-571 (2007).
8. Mitra AP, Lin H, Datar RH, Cote RJ. Molecular biology of bladder cancer: prognostic and clinical implications. Clin. Genitourin. Cancer 5(1), 67-77 (2006).
9. Roos PH, Golka K, Hengstler JG. Predictive biomarkers and signatures in urinary bladder cancer. Curr. Opin. Mol. Ther. 10, 243-250 (2008). (Pubitemid 351799275)
10. Roos PH. Molecular markers as diagnostic, prognostic and susceptibility predictors in bladder cancer. Eur. Urol. Rev. 3, 34-38 (2008).
11. Cordon-Cardo C. Molecular alterations associated with bladder cancer initiation and progression. Scand. J. Urol. Nephrol. 218(Suppl.), 154-165 (2008).
12. Pisitkun T, Johnstone R, Knepper MA. Discovery of urinary biomarkers. Mol. Cell Proteomics 5, 1760-1771 (2006). (Pubitemid 44688186)
13. Tyan YC, Guo HR, Liu CY, Liao PC. Proteomic profiling of human urinary proteome using nano-high performance liquid chromatography/electrospray ionization tandem mass spectrometry. Anal. Chim. Acta 579, 158-176 (2006).
14. Osman I, Bajorin DF, Sun TT, et al. Novel blood biomarkers of human urinary bladder cancer. Clin. Cancer Res. 12, 3374-3380 (2006).
15. Schwamborn K, Krieg RC, Grosse J, et al. Serum proteomic profiling in patients with bladder cancer. Eur. Urol. 56, 989-997 (2009).
16. Thongboonkerd V. Practical points in urinary proteomics. J. Proteome Res. 6(10), 3881-3890 (2007). (Pubitemid 350032551)
17. Thongboonkerd V, Mungdee S, Chiangjong W. Should urine pH be adjusted prior to gel-based proteome analysis? J. Proteome Res. 8(6), 3206-3211 (2009).
18. Havanapan PO, Thongboonkerd V. Are protease inhibitors required for gel-based proteomics of kidney and urine? J. Proteome Res. 8(6), 3109-3117 (2009).
19. West-Nielsen M, Høgdall EV, Marchiori E, Høgdall CK, Schou C, Heegaard NH. Sample handling for mass spectrometric proteomic investigations of human sera. Anal. Chem. 77(16), 5114-5123 (2005). (Pubitemid 41140826)
20. Ostroff R, Foreman T, Keeney TR, Stratford S, Walker JJ, Zichi D. The stability of the circulating human proteome to variations in sample collection and handling procedures measured with an aptamer-based proteomics array. J. Proteomics DOI: 10.1016/j. jprot.2009.09.004 (2009) (Epub ahead of print).
21. Hsieh SY, Chen RK, Pan YH, Lee HL. Systematical evaluation of the effects of sample collection procedures on low-molecular-weight serum/plasma proteome profiling. Proteomics 6(10), 3189-3198 (2006).
22. Pieper R, Gatlin CL, McGrath AM, et al. Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics 4(4), 1159-1174 (2004). (Pubitemid 38445973)
23. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell Proteomics 1(11), 845-867 (2002).
24. Liu BC, Ehrlich JR. Proteomics approaches to urologic diseases. Expert Rev. Proteomics 3(3), 283-296 (2006). (Pubitemid 43979403)
25. Ahmed N, Rice GE. Strategies for revealing lower abundance proteins in two-dimensional protein maps. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 815(1-2), 39-50 (2005). (Pubitemid 40126391)
26. Schiffer E, Mischak H, Theodorescu D, Vlahou A. Challenges of using mass spectrometry as a bladder cancer biomarker discoveryplatform. World J. Urol. 26(1), 67-74 (2008).
27. Barboro P, Rubagotti A, Orecchia P, et al. Differential proteomic analysis of nuclear matrix in muscle-invasive bladder cancer: potential to improve diagnosis and prognosis. Cell Oncol. 30(1), 13-26 (2008). (Pubitemid 351161036)
28. Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol. 7(9), R80 (2006).
29. Corthals GL, Wasinger VC, Hochstrasser DF, Sanchez JC. The dynamic range of protein expression: a challenge for proteomic research. Electrophoresis 21(6), 1104-1115 (2000). (Pubitemid 30230776)
30. Rasmussen HH, Orntoft TF, Wolf H, Celis JE. Towards a comprehensive database of proteins from the urine of patients with bladder cancer. J. Urol. 155(6), 2113-2119 (1996). (Pubitemid 26146717)
31. Getzenberg RH, Konety BR, Oeler TA, et al. Bladder cancer-associated nuclear matrix proteins. Cancer Res. 56(7), 1690-1694 (1996). (Pubitemid 26104035)
32. Orenes-Piñero E, Corton M, Gonzalez RS, Peramato P, et al. Searching urinary tumor markers for bladder cancer using a two-dimensional differential gel electrophoresis (2D-DIGE) approach. J. Proteome Res. 6, 4440-4448 (2007). (Pubitemid 350158519)
33. Ru QC, Katenhusen RA, Zhu LA, et al. Proteomic profiling of human urine using multi-dimensional protein identification technology. J. Chromatogr. A 1111(2), 166-174 (2006).
34. Saito M, Kimoto M, Araki T, et al. Proteome analysis of gelatin-bound urinary proteins from patients with bladder cancers. Eur. Urol. 48(5), 865-871 (2005). (Pubitemid 41495397)
35. Liu BC, Ehrlich JR. Proteomics approaches to urologic diseases. Expert Rev. Proteomics 3(3), 283-296 (2006). (Pubitemid 43979403)
36. Soldi M, Sarto C, Valsecchi C, et al. Proteome profile of human urine with two-dimensional liquid phase fractionation. Proteomics 5(10), 2641-7 (2005). (Pubitemid 40966491)
37. Kreunin P, Zhao J, Rosser C, Urquidi V, Lubman DM, Goodison S. Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J. Proteome Res. 6, 2631-2639 (2007). (Pubitemid 47122358)
38. Li C, Simeone DM, Brenner DE, et al. Pancreatic cancer serum detection using a lectin/glyco-antibody array method. J. Proteome Res. 11 (2008).
39. Vlahou A, Schellhammer PF, Mendrinos S, et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am. J. Pathol. 158(4), 1491-1502 (2001). (Pubitemid 32281313)
40. Vlahou A, Giannopoulos A, Gregory BW, et al. Protein profiling in urine for the diagnosis of bladder cancer. Clin. Chem. 50(8), 1438-1441 (2004). (Pubitemid 38970660)
41. Liu W, Guan M, Wu D, et al. Using tree analysis pattern and SELDI-TOF-MS to discriminate transitional cell carcinoma of the bladder cancer from noncancer patients. Eur. Urol. 47(4), 456-462 (2005). (Pubitemid 40357888)
42. Munro NP, Cairns DA, Clarke P, et al. Urinary biomarker profiling in transitional cell carcinoma. Int. J. Cancer 119(11), 2642-2650 (2006). (Pubitemid 44691320)
43. Müller J, von Eggeling F, Driesch D, Schubert J, Melle C, Junker K. ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients. Eur. Urol. 47(6), 885-893 (2005).
44. Zhang YF, Wu DL, Guan M, et al. Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient. Clin. Biochem. 37(9), 772-779 (2004). (Pubitemid 39141118)
45. Schiffer E, Mischak H, Theodorescu D, Vlahou A. Challenges of using mass spectrometry as a bladder cancer biomarker discovery platform. World J. Urol. 26(1), 67-74 (2008).
46. Smalley DM, Sheman NE, Nelson K, Theodorescu D. Isolation and identification of potential urinary microparticle biomarkers of bladder cancer. J. Proteome Res. 7(5), 2088-2096 (2008).
47. Sanchez-Carbayo M, Socci ND, Lozano JJ, Haab BB, Cordon-Cardo C. Profiling bladder cancer using targeted antibody arrays. Am. J. Pathol. 168(1), 93-103 (2006). (Pubitemid 43062562)
48. Margel D, Tal R, Baniel J. Serum tumor markers may predict overall and disease specific survival in patients with clinically organ confined invasive bladder cancer. J. Urol. 178, 2297-2300 (2007).
49. Sakaki M, Oka N, Nakanishi R, Yamaguchi K, Fukumori T, Kanayama HO. Serum level of galectin-3 in human bladder cancer. J. Med. Invest. 55(1-2), 127-132 (2008). (Pubitemid 351643603)
50. Hanke M, Hoefig K, Merz H, et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol. Oncol. DOI: 10.1016/j. urolonc.2009.01.027 (2009) (Epub ahead of print).
51. Mengual L, Burset M, Ars E, et al. Partially degraded RNA from bladder washing is a suitable sample for studying gene expression profiles in bladder cancer. Eur. Urol. 50(6), 1347-1355 (2006).
52. Dörrenhaus A, Theegarten D, Roos PH. Isolation of exfoliated human urothelial and Kidney cells from urine and their use for scientific and diagnostic purposes. Arch. Pharmacol. 372(Suppl. 1), 129-130 (2006).
53. Mengual L, Burset M, Ars E, et al. DNA microarray expression profiling of bladder cancer allows identification of noninvasive diagnostic markers. J. Urol. 182(2), 741-748 (2009).
54. Holyoake A, O'Sullivan P, Pollock R, et al. Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder. Clin. Cancer Res. 1, 14(3), 742-749 (2008). (Pubitemid 351231155)
55. Hanke M, Kausch I, Dahmen G, Jocham D, Warnecke JM. Detailed technical analysis of urine RNA-based tumor diagnostics reveals ETS2/urokinase plasminogen activator to be a novel marker for bladder cancer. Clin. Chem. 53(12), 2070-2077 (2007). (Pubitemid 350197289)
56. Pu XY, Wang ZP, Chen YR, Wang XH, Wu YL, Wang HP. The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine. J. Cancer Res. Clin. Oncol. 134(6), 659-665 (2008).
57. Mitra AP, Cote RJ. Molecular pathogenesis and diagnostics of bladder cancer. Annu. Rev. Pathol. 4, 251-285 (2009).
58. Rosser CJ, Liu L, Sun Y, et al. Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia. Cancer Epidemiol. Biomarkers Prev. 18(2), 444-453 (2009).
59. Copois V, Bibeau F, Bascoul-Mollevi C, et al. Impact of RNA degradation on gene expression profiles: assessment of different methods to reliably determine RNA quality. J. Biotechnol. 127(4), 549-559 (2007). (Pubitemid 44959110)
60. Jalali Nadoushan MR, Taheri T, Jouian N, Zaeri F. Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder. Urol. J. 4(3), 151-154 (2007).
61. Hansel DE, Swain E, Dreicer R, Tubbs RR. HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases. Am. J. Clin. Pathol. 130(2), 274-281 (2008).
62. Wagner F, Radelof U. Performance of different small sample RNA amplification techniques for hybridization on Affymetrix GeneChips. J. Biotechnol. 129(4), 628-634 (2007). (Pubitemid 46590458)
63. Gold D, Coombes K, Medhane D, et al. A comparative analysis of data generated using two different target preparation methods for hybridization to high-density oligonucleotide microarrays. BMC Genomics 5, 2 (2004).
64. O'Driscoll L. Extracellular nucleic acids and their potential as diagnostic, prognostic and predictive biomarkers. Anticancer Res. 27(3A), 1257-1265 (2007).
65. Gottardo F, Liu CG, Ferracin M, et al. Micro-RNA profiling in kidney and bladder cancers. Urol. Oncol. 25, 387-392 (2007). (Pubitemid 47362758)
66. Neely LA, Rieger-Christ KM, Neto BS, et al. A microRNA expression ratio defining the invasive phenotype in bladder tumors. Urol. Oncol. 15 (2008) (Epub ahead of print).
67. Li J, Smyth P, Flavin R, et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol. 7, 36 (2007).
68. Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. PLoS One 3(9), e3148 (2008).
69. Orum H, Nielsen PE, Egholm M, Berg RH, Buchardt O, Stanley C. Single base pair mutation analysis by PNA directed PCR clamping. Nucleic Acids Res. 21(23), 5332-5336 (1993). (Pubitemid 23348594)
70. Iacobuzio-Donahue CA. Epigenetic changes in cancer. Annu. Rev. Pathol. 4, 229-249 (2009).
71. Kim WJ, Kim YJ. Epigenetic biomarkers in urothelial bladder cancer. Expert Rev. Mol. Diagn. 9(3), 259-269 (2009).
72. Hoque MO, Begum S, Topaloglu O, et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J. Natl Cancer Inst. 98(14), 996-1004 (2006). (Pubitemid 44288164)
73. Yu J, Zhu T, Wang Z, et al. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin. Cancer Res. 13(24), 7296-7304 (2007).
74. Kim YK, Kim WJ. Epigenetic markers as promising prognosticators for bladder cancer. Int. J. Urol. 16(1), 17-22 (2009).
75. Rauch TA, Pfeifer GP. The MIRA method for DNA methylation analysis. Methods Mol. Biol. 507:65-75 (2009).
76. Brait M, Begum S, Carvalho AL, et al. Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer. Cancer Epidemiol. Biomarkers Prev. 17(10), 2786-2794 (2008).
77. Miyake M, Sugano K, Kawashima K, et al. Sensitive detection of FGFR3 mutations in bladder cancer and urine sediments by peptide nucleic acid-mediated real-time PCR clamping. Biochem. Biophys. Res. Commun. 362(4), 865-871 (2007). (Pubitemid 47390654)
78. Junker K, van Oers JM, Zwarthoff EC, Kania I, Schubert J, Hartmann A. Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations. Neoplasia 10(1), 1-7 (2008). (Pubitemid 351170708)
79. Wu TL, Zhang D, Chia JH, Tsao KH, Sun CF, Wu JT. Cell-free DNA: measurement in various carcinomas and establishment of normal reference range. Clin. Chim. Acta 321(1-2), 77-87 (2002). (Pubitemid 34597056)
80. Ellinger J, Bastian PJ, Ellinger N, et al. Apoptotic DNA fragments in serum of patients with muscle invasive bladder cancer: a prognostic entity. Cancer Lett. 264(2), 274-280 (2008).
81. Nezos A, Pissimisis N, Lembessis P, et al. Detection of circulating tumor cells in bladder cancer patients. Cancer Treat. Rev. 35(3), 272-279 (2008).
82. Wehler TC, Karg M, Distler E, et al. Rapid identification and sorting of viable virus-reactive CD4(+) and CD8(+) T cells based on antigen-triggered CD137 expression. J. Immunol. Methods 339(1), 23-37 (2008).
83. Zhu L, Loo WT, Chow LW. Circulating tumor cells in patients with breast cancer: possible predictor of micro-metastasis in bone marrow but not in sentinel lymph nodes. Biomed. Pharmacother. 59 Suppl 2, S355-S358 (2005).
84. Wang GY, Li Y, Yu YM, et al. Detection of disseminated tumor cells in bone marrow of gastric cancer using magnetic activated cell sorting and fluorescent activated cell sorting. J. Gastroenterol. Hepatol. 24(2), 299-306 (2009).
85. Yuasa T, Yoshiki T, Isono T, Tanaka T, Hayashida H, Okada Y. Expression of transitional cell-specific genes, uroplakin Ia and II, in bladder cancer: detection of circulating cancer cells in the peripheral blood of metastatic patients. Int. J. Urol. 6(6), 286-292 (1999). (Pubitemid 29273841)
86. Gazzaniga P, Gandini O, Giuliani L, et al. Detection of epidermal growth factor receptor mRNA in peripheral blood: a new marker of circulating neoplastic cells in bladder cancer patients. Clin. Cancer. Res. 7(3), 577-583 (2001). (Pubitemid 32707981)
87. Loberg RD, Fridman Y, Pienta BA, et al. Detection and isolation of circulating tumor cells in urologic cancers: a review. Neoplasia 6(4), 302-309 (2004). (Pubitemid 38924845)
88. Romih R, Korosec P, de Mello W Jr, Jezernik K. Differentiation of epithelial cells in the urinary tract. Cell Tissue Res. 320(2), 259-268 (2005). (Pubitemid 40684752)
89. Wu XR, Kong XP, Pellicer A, Kreibich G, Sun TT. Uroplakins in urothelial biology, function, and disease. Kidney Int. 75(11), 1153-1165 (2009).
90. Romih R, Veranic P, Jezernik K. Appraisal of differentiation markers in urothelial cells. Appl. Immunohistochem. Mol. Morphol. 10(4), 339-343 (2002). (Pubitemid 35453693)
91. Baffa R, Letko J, McClung C, LeNoir J, Vecchione A, Gomella LG. Molecular genetics of bladder cancer: targets for diagnosis and therapy. J. Exp. Clin. Cancer Res. 25, 145-160 (2006). (Pubitemid 44113858)
92. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J. Clin. Oncol. 24(35), 5552-5564 (2006). (Pubitemid 46631336)
93. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24(33), 5218-5225 (2005). (Pubitemid 41192438)
94. Schmitz-Dräger BJ, Kushima M, Goebell P, et al. p53 and MDM2 in the development and progression of bladder cancer. Eur. Urol. 32, 487-493 (1997). (Pubitemid 27501052)
95. Lim YP. Mining the tumor phosphoproteome for cancer markers. Clin. Cancer Res. 11(9), 3163-3169 (2005). (Pubitemid 40627861)
96. Sykora C, Hoffmann R, Hoffmann P. Enrichment of multiphosphorylated peptides by immobilized metal affinity chromatography using Ga(III)- and Fe(III)-complexes. Protein Pept. Lett. 14(5), 489-496 (2007). (Pubitemid 46833877)
97. Aryal UK, Olson DJ, Ross AR. Optimization of immobilized gallium (III) ion affinity chromatography for selective binding and recovery of phosphopeptides from protein digests. J. Biomol. Tech. 19(5), 296-310 (2008).
98. Emgenbroich M, Borrelli C, Shinde S, et al. A phosphotyrosine-imprinted polymer receptor for the recognition of tyrosine phosphorylated peptides. Chemistry 14(31), 9516-9529 (2008).
99. Irish JM, Hovland R, Krutzik PO, et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 118(2), 217-228 (2004). (Pubitemid 38962577)
100. Krutzik PO, Crane JM, Clutter MR, Nolan GP. High-content single-cell drug screening with phosphospecific flow cytometry. Nat. Chem. Biol. 4(2), 132-142 (2008).
101. Peter JF, Otto AM, Wolf B. Enrichment and detection of molecules secreted by tumor cells using magnetic reversed-phase particles and LC-MALDI-TOF-MS. J. Biomol. Tech. 18(5), 287-297 (2007).
102. Chan KS, Espinosa I, Chao M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl Acad. Sci. USA 106(33), 14016-14021 (2009).
103. Yu L, Huang H, Dong X, Wu D, Qin J, Lin B. Simple, fast and high-throughput single-cell analysis on PDMS microfluidic chips. Electrophoresis 29(24), 5055-5060 (2008).
104. Liu W, Dechev N, Foulds IG, Burke R, Parameswaran A, Park EJ. A novel permalloy based magnetic single cell micro array. Lab. Chip 9(16), 2381-2390 (2009).
105. Schumann CA, Dörrenhaus A, Franzke J, et al. Concomitant detection of CYP1A1 enzymatic activity and CYP1A1 protein in individual cells of a human urothelial cell line using a bilayer microfluidic device. Anal. Bioanal. Chem. 392(6), 1159-1166 (2008).
106. Lu J, Tsourkas A. Imaging individual microRNAs in single mammalian cells in situ. Nucleic Acids Res. 37(14), e100 (2009).
107. Ehdaie B, Theodorescu D. Predicting tumor outcomes in urothelial bladder carcinoma. turning pathways into clinical biomarkers of prognosis. Expert Rev. Anticancer Ther. 8, 1103-1110 (2008).
108. Bandura DR, Baranov VI, Ornatsky OI, et al. Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. Anal. Chem. 81, 6813-6822 (2009).
109. Jakubowski N, Roos PH. Method and diagnostic kit for simultaneous identification and quantification of individual biomolecules or biomolecules which are present in mixtures and their modifications. PCT/EP2007/050254 and DE 10 2006 001 793.5 (2007).